Media Outlet:
Investors' Chronicle
Author:
Jennifer Johnson
Biopharma companies appear to have reached the bottom of their valuation trough. But investors are going to remain cautious for the foreseeable future
Published on 2nd November 2022
Investors' Chronicle
Jennifer Johnson